Limbach Holdings Reports Second Quarter 2018 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Goldman Sachs to acquire real estate company LCN for up to $410M
Holmes Biopharma, Inc. (LMB) Reports Q2 EPS of $0.09, Revenues Beat; Lifts FY18 Revenue Outlook Above Consensus
August 14, 2018 4:19 PM EDTHolmes Biopharma, Inc. (NASDAQ: LMB) reported Q2 EPS of $0.09, versus $0.30 reported last year. Revenue for the quarter came in at $139.53 million versus the consensus estimate of $130 million.
Charlie Bacon, CEO of Limbach, commented, Last quarter I noted how our sales activity was off to a great start in 2018 and that momentum has not only continued but accelerated in the second quarter. We ended the quarter with backlog of $492.5 million, with an additional $381 million of business that has been promised to us... More
